Serviços Personalizados
Journal
Artigo
Indicadores
- Citado por SciELO
- Acessos
Links relacionados
- Citado por Google
- Similares em SciELO
- Similares em Google
Compartilhar
Revista colombiana de Gastroenterología
versão impressa ISSN 0120-9957versão On-line ISSN 2500-7440
Resumo
GUERRERO-S, Silvia; ACEVEDO, Juan Javier; FACUNDO-NAVIA, Helena e GUEVARA-CRUZ, Óscar Alexander. KRAS Gene Mutation in Patients Undergoing Liver Resections for Colorectal Cancer. Is There an Advantage to Anatomical Resections?. Rev. colomb. Gastroenterol. [online]. 2023, vol.38, n.1, pp.19-27. Epub 06-Jun-2023. ISSN 0120-9957. https://doi.org/10.22516/25007440.929.
Introduction:
Several factors have been described to make a prognostic assessment of patients with liver metastases due to colorectal cancer and to define the benefit of the surgical management of metastatic involvement; one of these factors is the status of the KRAS gene since its mutation is associated with worse outcomes. This study aims to describe the outcomes for a retrospective series of patients after liver resections for metastatic colorectal cancer concerning KRAS gene status.
Materials and methods:
The study involves a retrospective cohort of patients undergoing liver metastasectomy for colorectal cancer with KRAS mutation study from 2009-2013 at the National Institute of Cancerology in Colombia. Five-year survival analyses (overall and disease-free) were performed according to KRAS mutation status and the type of liver resection performed using the Kaplan-Meier estimate.
Results:
35 patients undergoing liver metastasectomy were analyzed, of which 42.8% had KRAS gene mutation. Median overall survival was 34.2 months for patients with KRAS- mutant and 46.5 for non-mutant. The median survival for KRAS-mutant patients with anatomic resections was 43.5 months versus 23.5 months for nonanatomic resections.
Conclusions:
Performing anatomic resections during liver metastasectomy in patients with KRAS mutants could be associated with an improvement in overall survival. It is necessary to continue building the evidence for adequate decision-making in patients with KRAS mutants who will undergo liver resections.
Palavras-chave : Colorectal cancer; liver metastases; metastasectomy; KRAS mutation.